{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:36:41Z","timestamp":1785544601554,"version":"3.56.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773192"],"award-info":[{"award-number":["81773192"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072712"],"award-info":[{"award-number":["82072712"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002949","name":"Government of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20171248"],"award-info":[{"award-number":["BK20171248"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018592","name":"\u201c333 Project\u201d of Jiangsu Province","doi-asserted-by":"publisher","award":["2016-III-0367"],"award-info":[{"award-number":["2016-III-0367"]}],"id":[{"id":"10.13039\/501100018592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.retram.2021.103320","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:25:13Z","timestamp":1636417513000},"page":"103320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3840-9998","authenticated-orcid":false,"given":"Le","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6382","key":"10.1016\/j.retram.2021.103320_bib0001","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.retram.2021.103320_bib0002","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.retram.2021.103320_bib0003","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1158\/1078-0432.CCR-19-1339","article-title":"Sustained therapeutic efficacy of humanized anti-CD19 chimeric antigen receptor T cells in relapsed\/refractory acute lymphoblastic leukemia","volume":"26","author":"Heng","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"0","key":"10.1016\/j.retram.2021.103320_bib0004","article-title":"Tragedy, perseverance, and chance\u2014the story of CAR-T therapy","volume":"377","author":"Rosenbaum","year":"2017","journal-title":"N Engl J Med"},{"issue":"95","key":"10.1016\/j.retram.2021.103320_bib0005","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"20","key":"10.1016\/j.retram.2021.103320_bib0006","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.retram.2021.103320_bib0007","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.retram.2021.103320_bib0008","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2021.103320_bib0009","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.3389\/fimmu.2020.564099","article-title":"Phase I trial of fourth-generation anti-CD19 chimeric antigen receptor T cells against relapsed or refractory B cell non-hodgkin lymphomas","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Immunol"},{"issue":"26","key":"10.1016\/j.retram.2021.103320_bib0010","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.retram.2021.103320_bib0011","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.retram.2021.103320_bib0012","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.retram.2021.103320_bib0013","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.retram.2021.103320_bib0014","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.retram.2021.103320_bib0015","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.retram.2021.103320_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.retram.2021.103320_bib0017","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.3389\/fimmu.2020.01965","article-title":"Use of cell and genome modification technologies to generate improved \u201coff-the-shelf\u201d CAR T and CAR NK Cells","volume":"11","author":"Morgan","year":"2020","journal-title":"Front Immunol"},{"issue":"21","key":"10.1016\/j.retram.2021.103320_bib0018","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.retram.2021.103320_bib0019","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"10.1016\/j.retram.2021.103320_bib0020","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.retram.2021.103320_bib0021","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR\u2013T cells of defined CD4+: CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.retram.2021.103320_bib0022","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.retram.2021.103320_bib0023","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2019003293","article-title":"Sequential CD19-22 CAR T therapy induces sustained remission in children with r\/r B-ALL","volume":"135","author":"Pan","year":"2020","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.retram.2021.103320_bib0024","doi-asserted-by":"crossref","first-page":"7222","DOI":"10.3390\/ijms21197222","article-title":"Modular chimeric antigen receptor systems for universal CAR T cell retargeting","volume":"21","author":"Sutherland","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"19","key":"10.1016\/j.retram.2021.103320_bib0025","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1182\/bloodadvances.2020002292","article-title":"Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy","volume":"4","author":"Chow","year":"2020","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.retram.2021.103320_bib0026","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1038\/s41375-020-0760-x","article-title":"Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy","volume":"34","author":"Libert","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.retram.2021.103320_bib0027","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/bjh.17382","article-title":"Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease","volume":"193","author":"Mikhailova","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.retram.2021.103320_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21168-6","article-title":"Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy","volume":"12","author":"Rabilloud","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.retram.2021.103320_bib0029","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","article-title":"CAR-T cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease","volume":"13","author":"Pehlivan","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.retram.2021.103320_bib0030","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fonc.2019.00146","article-title":"Multi targeted CAR-T cell therapies for B-cell malignancies","volume":"9","author":"Shah","year":"2019","journal-title":"Front Oncol"},{"issue":"16","key":"10.1016\/j.retram.2021.103320_bib0031","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.retram.2021.103320_bib0032","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1182\/blood-2018-99-115351","article-title":"Aged CAR T cells exhibit enhanced cytotoxicity and effector function but shorter persistence and less memory-like phenotypes","volume":"132","author":"Kotani","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2021.103320_bib0033","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-117493","article-title":"Starting T cell and cell product phenotype are associated with durable remission of leukemia following CD19 CAR-T cell immunotherapy","volume":"132","author":"Gardner","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.retram.2021.103320_bib0034","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.retram.2021.103320_bib0035","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9967","key":"10.1016\/j.retram.2021.103320_bib0036","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet North Am Ed"},{"issue":"7","key":"10.1016\/j.retram.2021.103320_bib0037","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"Van Der Stegen","year":"2015","journal-title":"Nat Rev Drug Discovery"},{"issue":"4","key":"10.1016\/j.retram.2021.103320_bib0038","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.retram.2021.103320_bib0039","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.retram.2021.103320_bib0040","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.retram.2021.103320_bib0041","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"10.1016\/j.retram.2021.103320_bib0042","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.ymthe.2017.07.009","article-title":"Adnectin-based design of chimeric antigen receptor for T cell engineering","volume":"25","author":"Han","year":"2017","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.retram.2021.103320_bib0043","first-page":"1","article-title":"Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains","volume":"11","author":"Lam","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.retram.2021.103320_bib0044","unstructured":"Gardner R, Finney O, Smithers H, Leger KJ, Annesley CE, Summers C et\u00a0al. (American Society of Hematology Washington, DC, 2016)."},{"issue":"12","key":"10.1016\/j.retram.2021.103320_bib0045","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.retram.2021.103320_bib0046","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ccell.2017.03.002","article-title":"Harnessing the immunotherapy revolution for the treatment of childhood cancers","volume":"31","author":"Majzner","year":"2017","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.retram.2021.103320_bib0047","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CJI.0000000000000169","article-title":"CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis","volume":"40","author":"Fischer","year":"2017","journal-title":"J Immunother"},{"issue":"18","key":"10.1016\/j.retram.2021.103320_bib0048","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2017-05-782888","article-title":"Hematopoietic stem cell involvement in BCR-ABL1\u2013positive ALL as a potential mechanism of resistance to blinatumomab therapy","volume":"130","author":"Nagel","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.retram.2021.103320_bib0049","doi-asserted-by":"crossref","first-page":"e26594","DOI":"10.1002\/pbc.26594","article-title":"Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement","volume":"64","author":"Zoghbi","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"issue":"10","key":"10.1016\/j.retram.2021.103320_bib0050","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.retram.2021.103320_bib0051","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/cancers12051075","article-title":"Overcoming heterogeneity of antigen expression for effective CAR T cell targeting of cancers","volume":"12","author":"Kailayangiri","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.retram.2021.103320_bib0052","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4049\/jimmunol.1402346","article-title":"Target antigen density governs the efficacy of anti\u2013CD20-CD28-CD3 \u03b6 chimeric antigen receptor\u2013modified effector CD8+ T cells","volume":"194","author":"Watanabe","year":"2015","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.retram.2021.103320_bib0053","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/mt.2016.82","article-title":"Superior therapeutic index in lymphoma therapy: CD30+ CD34+ hematopoietic stem cells resist a chimeric antigen receptor T-cell attack","volume":"24","author":"Hombach","year":"2016","journal-title":"Mol Ther"},{"issue":"7750","key":"10.1016\/j.retram.2021.103320_bib0054","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.retram.2021.103320_bib0055","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"399","key":"10.1016\/j.retram.2021.103320_bib0056","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.retram.2021.103320_bib0057","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","article-title":"Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase","volume":"25","author":"Walker","year":"2017","journal-title":"Mol Ther"},{"issue":"12","key":"10.1016\/j.retram.2021.103320_bib0058","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1038\/cti.2016.73","article-title":"All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia","volume":"5","author":"Yoshida","year":"2016","journal-title":"Clin Transl Immunol"},{"issue":"17","key":"10.1016\/j.retram.2021.103320_bib0059","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-18-3784","article-title":"Modulation of target antigen density improves CAR T-cell functionality and persistence","volume":"25","author":"Ramakrishna","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.retram.2021.103320_bib0060","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3324\/haematol.2011.049155","article-title":"The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-\u03b2II depletion","volume":"97","author":"Biberacher","year":"2012","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2021.103320_bib0061","article-title":"Modulation of CD22 antigen density improves efficacy of CD22 chimeric antigen receptor (CAR) T cells against CD22lo B-lineage leukemia and lymphoma","volume":"130","author":"Ramakrishna","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.retram.2021.103320_bib0062","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.retram.2021.103320_bib0063","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-018-3546-8","article-title":"Navigating the treatment landscape in multiple myeloma: which combinations to use and when?","volume":"98","author":"Goldschmidt","year":"2019","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.retram.2021.103320_bib0064","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood-2018-08-825349","article-title":"Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing","volume":"133","author":"Kumar","year":"2019","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.retram.2021.103320_bib0065","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.retram.2021.103320_bib0066","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.retram.2021.103320_bib0067","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.retram.2021.103320_bib0068","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1182\/blood-2010-07-294520","article-title":"Immune responses to transgene and retroviral vector in patients treated with ex vivo\u2013engineered T cells","volume":"117","author":"Lamers","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.retram.2021.103320_bib0069","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","article-title":"T cells expressing chimeric antigen receptors can cause anaphylaxis in humans","volume":"1","author":"Maus","year":"2013","journal-title":"Cancer Immunol Res"},{"issue":"355","key":"10.1016\/j.retram.2021.103320_bib0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor\u2013modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.retram.2021.103320_bib0071","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol Ther"},{"issue":"10","key":"10.1016\/j.retram.2021.103320_bib0072","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/leu.2017.57","article-title":"Fully human CD19-specific chimeric antigen receptors for T-cell therapy","volume":"31","author":"Sommermeyer","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.retram.2021.103320_bib0073","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nbt1142","article-title":"Engineered antibody fragments and the rise of single domains","volume":"23","author":"Holliger","year":"2005","journal-title":"Nat Biotechnol"},{"issue":"14","key":"10.1016\/j.retram.2021.103320_bib0074","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1021\/acs.jmedchem.0c02054","article-title":"Optimization of CAR-T cell-based therapies using small-molecule-based safety switches","volume":"64","author":"Zheng","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.retram.2021.103320_bib0075","first-page":"1","article-title":"Next-generation CAR T cells to overcome current drawbacks","author":"Lundh","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.retram.2021.103320_bib0076","unstructured":"Lee III DW, Stetler-Stevenson M, Yuan CM, Shah NN, Delbrook C, Yates B et\u00a0al. (American Society of Hematology Washington, DC, 2016)."},{"key":"10.1016\/j.retram.2021.103320_bib0077","doi-asserted-by":"crossref","DOI":"10.5582\/bst.2018.01048","article-title":"Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer","author":"Chu","year":"2018","journal-title":"Biosci Trends"},{"issue":"8","key":"10.1016\/j.retram.2021.103320_bib0078","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1021\/jacs.5b00106","article-title":"Redirection of genetically engineered CAR-T cells using bifunctional small molecules","volume":"137","author":"Kim","year":"2015","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.retram.2021.103320_bib0079","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fonc.2019.00151","article-title":"Preclinical evaluation of bispecific adaptor molecule controlled folate receptor CAR-T cell therapy with special focus on pediatric malignancies","volume":"9","author":"Lu","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.retram.2021.103320_bib0080","unstructured":"Low PS, Luo Q, Napoleon JV, Zhang B, in Cancer Res. (AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA \u2026, 2020), vol. 80."},{"issue":"9","key":"10.1016\/j.retram.2021.103320_bib0081","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/2326-6066.CIR-21-0095","article-title":"CRASH-IT switch enables reversible and dose-dependent control of TCR and CAR T-cell function","volume":"9","author":"Sahillioglu","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.retram.2021.103320_bib0082","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.cell.2018.05.030","article-title":"Increasing T cell versatility with SUPRA CARs","volume":"173","author":"Chen","year":"2018","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.retram.2021.103320_bib0083","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.retram.2021.103320_bib0084","doi-asserted-by":"crossref","first-page":"E459","DOI":"10.1073\/pnas.1524155113","article-title":"Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies","volume":"113","author":"Rodgers","year":"2016","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"10.1016\/j.retram.2021.103320_bib0085","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.61","article-title":"Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts","volume":"6","author":"Cartellieri","year":"2016","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.retram.2021.103320_bib0086","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1342909","article-title":"Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model","volume":"6","author":"Pishali Bejestani","year":"2017","journal-title":"Oncoimmunology"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2021.103320_bib0087","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-113126","article-title":"Early clinical experience of CD19 x CD22 dual specific CAR T cells for enhanced anti-leukemic targeting of acute lymphoblastic leukemia","volume":"132","author":"Gardner","year":"2018","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.retram.2021.103320_bib0088","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.retram.2021.103320_bib0089","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.retram.2021.103320_bib0090","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ajh.24594","article-title":"Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma","volume":"92","author":"Yu","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.retram.2021.103320_bib0091","first-page":"127","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol Ther"},{"issue":"17","key":"10.1016\/j.retram.2021.103320_bib0092","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1158\/1078-0432.CCR-20-0305","article-title":"The role of antigen spreading in the efficacy of immunotherapies","volume":"26","author":"Brossart","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.retram.2021.103320_bib0093","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"26","key":"10.1016\/j.retram.2021.103320_bib0094","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"625","key":"10.1016\/j.retram.2021.103320_bib0095","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci Signal"},{"issue":"13","key":"10.1016\/j.retram.2021.103320_bib0096","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/0008-5472.CAN-11-0422","article-title":"In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)","volume":"71","author":"Song","year":"2011","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.retram.2021.103320_bib0097","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"issue":"24","key":"10.1016\/j.retram.2021.103320_bib0098","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.retram.2021.103320_bib0099","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3324\/haematol.2019.231183","article-title":"CD28. OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR. CD30 T cells","volume":"106","author":"Guercio","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.retram.2021.103320_bib0100","first-page":"60","article-title":"Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin\u2019s lymphoma","volume":"15","author":"Ying","year":"2019","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.retram.2021.103320_bib0101","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/mt.2016.63","article-title":"GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade","volume":"24","author":"Gargett","year":"2016","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.retram.2021.103320_bib0102","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol Ther"},{"issue":"22","key":"10.1016\/j.retram.2021.103320_bib0103","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","article-title":"Enhanced cancer immunotherapy by chimeric antigen receptor\u2013modified T cells engineered to secrete checkpoint inhibitors","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.retram.2021.103320_bib0104","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.12998\/wjcc.v9.i10.2394","article-title":"Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: a case report","volume":"9","author":"Niu","year":"2021","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.retram.2021.103320_bib0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.03.012","article-title":"Development of CAR T cells designed to improve antitumor efficacy and safety","volume":"178","author":"Jaspers","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"20","key":"10.1016\/j.retram.2021.103320_bib0106","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.3390\/ijms20205010","article-title":"Resistance mechanisms to CAR T-cell therapy and overcoming strategy in B-cell hematologic malignancies","volume":"20","author":"Song","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"6373","key":"10.1016\/j.retram.2021.103320_bib0107","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/357080a0","article-title":"Molecular and biological characterization of a murine ligand for CD40","volume":"357","author":"Armitage","year":"1992","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.retram.2021.103320_bib0108","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/PL00000776","article-title":"The CD40\/CD154 receptor\/ligand dyadRID=\u201c\u2020\u201d ID=\u201c\u2020\u201d review","volume":"58","author":"Sch\u00f6nbeck","year":"2001","journal-title":"Cell Mol Life Sci CMLS"},{"issue":"3","key":"10.1016\/j.retram.2021.103320_bib0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.02.006","article-title":"CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response","volume":"35","author":"Kuhn","year":"2019","journal-title":"Cancer Cell"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2021.103320_bib0110","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-117737","article-title":"A Phase I first-in-human clinical trial of CD19-targeted 19-28z\/4-1BBL armored CAR T cells in patients with relapsed or refractory NHL and CLL including Richter\u2019s transformation","volume":"132","author":"Park","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.retram.2021.103320_bib0111","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1042\/BST20150291","article-title":"Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy","volume":"44","author":"Yeku","year":"2016","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"10.1016\/j.retram.2021.103320_bib0112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16 ecto directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J Transl Med"},{"issue":"18","key":"10.1016\/j.retram.2021.103320_bib0113","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.retram.2021.103320_bib0114","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"26","key":"10.1016\/j.retram.2021.103320_bib0115","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.retram.2021.103320_bib0116","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.retram.2021.103320_bib0117","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.retram.2021.103320_bib0118","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1172\/JCI130144","article-title":"CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration","volume":"130","author":"Nobles","year":"2020","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.retram.2021.103320_bib0119","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4049\/jimmunol.1700559","article-title":"The loss of TET2 promotes CD8+ T cell memory differentiation","volume":"200","author":"Carty","year":"2018","journal-title":"J Immunol"},{"issue":"7709","key":"10.1016\/j.retram.2021.103320_bib0120","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"issue":"7632","key":"10.1016\/j.retram.2021.103320_bib0121","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nature20165","article-title":"S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate","volume":"540","author":"Tyrakis","year":"2016","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.retram.2021.103320_bib0122","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2021.06.012","article-title":"The role of exhaustion in CAR T cell therapy","volume":"39","author":"Delgoffe","year":"2021","journal-title":"Cancer Cell"},{"issue":"7786","key":"10.1016\/j.retram.2021.103320_bib0123","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.retram.2021.103320_bib0124","first-page":"1","article-title":"BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells","author":"Seo","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.retram.2021.103320_bib0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2020.12.004","article-title":"A metabolic switch to memory CAR T cells: Implications for cancer treatment","volume":"500","author":"Rostamian","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.retram.2021.103320_bib0126","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.retram.2021.103320_bib0127","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.retram.2021.103320_bib0128","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41375-019-0488-7","article-title":"CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia","volume":"33","author":"Pan","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.retram.2021.103320_bib0129","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.retram.2021.103320_bib0130","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.retram.2021.103320_bib0131","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1172\/JCI86721","article-title":"Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells","volume":"126","author":"Kebriaei","year":"2016","journal-title":"J Clin Invest"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318621000465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318621000465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:39:44Z","timestamp":1762821584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318621000465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":131,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2452318621000465"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2021.103320","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2021.103320","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103320"}}